On recordAs of Nov 11, 2026
Kevin Hern reported a $1,001 to $15,000 sale of stock.
In a dependent’s account, traded Mar 24, 2026 and disclosed Apr 3, 2026, 10 days later.

Congress trades
Medical Diagnostics & Research, listed on NASDAQ.
28 Congress trades · last filed Apr 3, 2026
Free on iOS and Android
Email me new Exact Sciences filings
An email on days Exact Sciences insiders file a trade or Exact Sciences reports results. One a day at most.
Check your inbox
We sent a link to your address. Tap it to confirm; we email nothing until you do.
Want it the moment it is filed? The app sends a push, free.
On recordAs of Nov 11, 2026
Kevin Hern reported a $1,001 to $15,000 sale of stock.
In a dependent’s account, traded Mar 24, 2026 and disclosed Apr 3, 2026, 10 days later.
EarningsQ4 FY2025 · reported Feb 13, 2026
Q4 FY2025: Miss on EPS. Revenue beat by 2.0%.
EPS Q4 FY2025
Revenue Q4 FY2025
Beat 3 · Miss 3
CongressSTOCK Act disclosures to the House and Senate
20 Congress disclosures shown, from 2 members.
| Quarter | EPS | EPS expected | Revenue | Revenue expected | Result |
|---|---|---|---|---|---|
| Q4 FY2025reported Feb 13, 2026 | -$0.45 | -$0.11 | $878.4M | $860.9M | EPS missRevenue beat |
| Q3 FY2025reported Nov 3, 2025 | $0.24 | -$0.06 | $850.7M | $810.5M | EPS beatRevenue beat |
| Q2 FY2025reported Aug 6, 2025 | $0.22 | -$0.02 | $811.1M | $810.1M | EPS beatRevenue in line |
| Q1 FY2025reported May 1, 2025 | -$0.54 | -$0.37 | $706.8M | $688.6M | EPS missRevenue beat |
| Q4 FY2024reported Feb 19, 2025 | -$0.06 | -$0.29 | $713.4M | $697.9M | EPS beatRevenue beat |
| Q3 FY2024reported Nov 5, 2024 | -$0.21 | -$0.20 | $708.7M | $716.8M | EPS missRevenue in line |
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag reads n/a only when a number is missing. An estimate is a forecast made by analysts, not a company target.
No earnings call briefs on EXAS yet. Briefs from every company we cover.
Past year Each firm's latest target, newest first
| Firm | Rating | Target | Action | Date |
|---|---|---|---|---|
| Mizuho | Neutral | $105 | Target set | |
| Evercore ISI | In Line | $105 | Target set | |
| Stifel | Hold | $105 | Target set | |
| Canaccord | Hold | $105 | Target set | |
| Piper Sandler | Neutral | $105 | Target set | |
| Jefferies | Hold | $105 | Target set | |
| Craig-Hallum | Hold | $105 | Target set | |
| Barclays | Equal Weight | $105 | Target set | |
| Wells Fargo | Equal Weight | $105 | Target set | |
| Baird | Neutral | $105 | Target set |
Each firm's latest target from the past year, with the rating stated with its note. These are the firms' own views, not GetSignal's, and we do not endorse them. Not investment advice.
4 other firms rated EXAS in the past year with no current target listed here. Ratings and targets come from licensed market data providers. A target is listed only after its firm and company are confirmed against a report of the note. As of Nov 11, 2026.
| Executive | Salary | Stock awards | Other | Total |
|---|---|---|---|---|
| Kevin ConroyChairman, President and Chief Executive Officer | $1.1M | $13.5M | $960K | $15.5M |
| Aaron BloomerExecutive Vice President and Chief Financial Officer | $432K | $6.0M | $752K | $7.2M |
| Jacob OrvilleExecutive Vice President and General Manager, Screening | $618K | $3.6M | $234K | $4.4M |
| Brian BaranickExecutive Vice President and General Manager, Precision Oncology | $600K | $3.6M | $218K | $4.4M |
| Sarah CondellaExecutive Vice President, Human Resources | $509K | $1.9M | $226K | $2.6M |
The summary compensation table from the proxy statement for fiscal 2024, with titles as filed then. 2 executives who have since left the company are named in that filing and not shown here. Read the filing
Since the trade: the stock's move from its estimated entry price (a purchase) or estimated exit price (a sale) to its current price, the latest close we hold. Not the member's result.
| Member | Type | Action | Amount disclosed | Since the trade | Trade date | Disclosed | Delay |
|---|---|---|---|---|---|---|---|
| Stock | Sale | $1,001 - $15,000 | n/aPrice history ends Mar 23, 2026 | Mar 24, 2026 | Apr 3, 2026 | 10d | |
| Stock | Sale | $1,001 - $15,000 | n/aPrice history ends Mar 23, 2026 | May 10, 2024 | Jun 8, 2024 | 29d | |
| Stock | Sale | $1,001 - $15,000 | n/aPrice history ends Mar 23, 2026 | Feb 1, 2024 | Mar 7, 2024 | 35d | |
| Stock | Sale | $1,001 - $15,000 | n/aPrice history ends Mar 23, 2026 | Jan 2, 2024 | Feb 11, 2024 | 40d | |
| Stock | Sale | $1,001 - $15,000 | n/aPrice history ends Mar 23, 2026 | Nov 13, 2023 | Dec 8, 2023 | 25d | |
| Stock | Purchase | $1,001 - $15,000 | n/aPrice history ends Mar 23, 2026 | Oct 16, 2023 | Nov 11, 2023 | 26d | |
| Stock | Sale | $1,001 - $15,000 | n/aPrice history ends Mar 23, 2026 | Sep 15, 2023 | Oct 15, 2023 | 30d | |
| Stock | Sale | $1,001 - $15,000 | n/aPrice history ends Mar 23, 2026 | May 1, 2023 | Jun 11, 2023 | 41d | |
| Stock | Purchase | $1,001 - $15,000 | n/aPrice history ends Mar 23, 2026 | Jan 20, 2023 | Feb 17, 2023 | 28d | |
| Stock | Sale | $1,001 - $15,000 | n/aPrice history ends Mar 23, 2026 | Jan 31, 2023 | Feb 14, 2023 | 14d | |
| Stock | Sale | $50,001 - $100,000 | n/aPrice history ends Mar 23, 2026 | Dec 19, 2022 | Jan 13, 2023 | 25d | |
| Stock | Sale | $1,001 - $15,000 | n/aPrice history ends Mar 23, 2026 | May 16, 2022 | Jun 14, 2022 | 29d | |
| Stock | Sale | $1,001 - $15,000 | n/aPrice history ends Mar 23, 2026 | Jun 3, 2021 | Jul 15, 2021 | 42d | |
| Stock | Purchase | $50,001 - $100,000 | n/aPrice history ends Mar 23, 2026 | May 20, 2021 | Jun 15, 2021 | 26d | |
| Stock | Purchase | $1,001 - $15,000 | n/aPrice history ends Mar 23, 2026 | May 20, 2021 | Jun 15, 2021 | 26d | |
| Stock | Purchase | $1,001 - $15,000 | n/aPrice history ends Mar 23, 2026 | Nov 11, 2020 | Dec 9, 2020 | 28d | |
| Stock | Purchase | $1,001 - $15,000 | n/aPrice history ends Mar 23, 2026 | Oct 26, 2020 | Nov 5, 2020 | 10d | |
| Stock | Sale | $1,001 - $15,000 | n/aPrice history ends Mar 23, 2026 | Sep 15, 2020 | Oct 13, 2020 | 28d | |
| Stock | Purchase | $1,001 - $15,000 | n/aPrice history ends Mar 23, 2026 | Jul 27, 2020 | Aug 15, 2020 | 19d | |
| Stock | Sale | $1,001 - $15,000 | n/aPrice history ends Mar 23, 2026 | Jun 2, 2020 | Jul 9, 2020 | 37d |
We hold no closing prices for any row shown here, so no move is shown. Not investment advice.
Estimated prices are the stock's closing price on the trade date. A disclosure gives a value band, not the price paid. Not investment advice. After a sale a positive figure means the stock kept rising after it. On an option line the prices are the stock's, never the option's: the premium is never disclosed.
A delay above 45 days is the gap between the dates on the report; we mark a filing late only after checking it.
"Not captured" means the band or the transaction type on the original report is missing from our data.
"Dates conflict" marks a row whose disclosure is dated before its trade on the record we hold. Both dates are printed as filed, and no prices or move are shown for that row.
Every Congress trade in EXAS filterable by party, chamber, type and account.
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
A STOCK Act disclosure gives each trade as a band of dollar values, which we do not narrow, and is due within 45 days of the trade. An option is described by its underlying company's name; its row says it is an option.
Data as of Nov 11, 2026.
What the filings on EXAS show and how current they are.
Kevin Hern and Josh Gottheimer disclosed EXAS transactions in the filings shown here.
Congressional disclosures took a median of 28 days, against the 45 the STOCK Act allows.